Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

[Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].

Lu FM, Tong ZL, Mao YM, Wu DY, Xu J.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012 Aug;29(4):478-81. doi: 10.3760/cma.j.issn.1003-9406.2012.04.022. Chinese.

PMID:
22875511
[PubMed - indexed for MEDLINE]
2.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiń≠ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
[PubMed - indexed for MEDLINE]
3.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Pharmacogenomics. 2009 Nov;10(11):1799-817. doi: 10.2217/pgs.09.143. Review.

PMID:
19891556
[PubMed - indexed for MEDLINE]
4.

Clopidogrel pharmacogenetics: metabolism and drug interactions.

Close SL.

Drug Metabol Drug Interact. 2011;26(2):45-51. doi: 10.1515/DMDI.2011.002. Review.

PMID:
21819266
[PubMed - indexed for MEDLINE]
5.

Drug-drug interaction between clopidogrel and the proton pump inhibitors.

Norgard NB, Mathews KD, Wall GC.

Ann Pharmacother. 2009 Jul;43(7):1266-74. doi: 10.1345/aph.1M051. Epub 2009 May 26. Review.

PMID:
19470853
[PubMed - indexed for MEDLINE]
6.

Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.

Fernando H, Dart AM, Peter K, Shaw JA.

Thromb Haemost. 2011 Jun;105(6):933-44. doi: 10.1160/TH10-11-0715. Epub 2011 May 5. Review.

PMID:
21544314
[PubMed - indexed for MEDLINE]
7.

Factors associated with clopidogrel nonresponsiveness.

Momary KM, Dorsch MP.

Future Cardiol. 2010 Mar;6(2):195-210. doi: 10.2217/fca.10.1. Review.

PMID:
20230261
[PubMed - indexed for MEDLINE]
8.

Clopidogrel and proton pump inhibitors: is there a significant drug-drug interaction?

Shmulevich E, Friger M, Gilutz H, Azab AN.

Can J Cardiovasc Nurs. 2011;21(4):27-36. Review.

PMID:
22165503
[PubMed - indexed for MEDLINE]
9.

Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?

Ma TK, Lam YY, Tan VP, Yan BP.

Br J Clin Pharmacol. 2011 Oct;72(4):697-706. doi: 10.1111/j.1365-2125.2011.03949.x. Review.

PMID:
21352268
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Genetic determinants of on-clopidogrel high platelet reactivity.

Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R.

Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Epub 2011 May 31. Review.

PMID:
21627411
[PubMed - indexed for MEDLINE]
11.

[Dilemma between gastroprotection and cardiovascular prevention].

Venerito M, Kandulski A, Malfertheiner P.

Dtsch Med Wochenschr. 2010 Nov;135(44):2193-8. doi: 10.1055/s-0030-1267498. Epub 2010 Oct 26. Review. German.

PMID:
20979006
[PubMed - indexed for MEDLINE]
12.

Drug interaction between clopidogrel and proton pump inhibitors.

Khalique SC, Cheng-Lai A.

Cardiol Rev. 2009 Jul-Aug;17(4):198-200. doi: 10.1097/CRD.0b013e3181a857ba. Review.

PMID:
19525682
[PubMed - indexed for MEDLINE]
13.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
[PubMed - indexed for MEDLINE]
14.

Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.

Hasan MS, Basri HB, Hin LP, Stanslas J.

Int J Neurosci. 2013 Mar;123(3):143-54. doi: 10.3109/00207454.2012.744308. Epub 2012 Dec 6. Review.

PMID:
23110469
[PubMed - indexed for MEDLINE]
15.

Personalized approaches to clopidogrel therapy: are we there yet?

Anderson CD, Biffi A, Greenberg SM, Rosand J.

Stroke. 2010 Dec;41(12):2997-3002. doi: 10.1161/STROKEAHA.110.594069. Epub 2010 Oct 28. Review.

PMID:
21030701
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J.

Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x. Review.

PMID:
20233192
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk